Docstoc

Ridgemont Equity Partners Acquires Majority Interest in Gallus BioPharmaceuticals

Document Sample
Ridgemont Equity Partners Acquires Majority Interest in Gallus BioPharmaceuticals Powered By Docstoc
					Ridgemont Equity Partners Acquires Majority
Interest in Gallus BioPharmaceuticals
May 18, 2011 12:04 PM Eastern Daylight Time 

CHARLOTTE, N.C.--(EON: Enhanced Online News)--Ridgemont Equity Partners (“Ridgemont”), a middle
market buyout and growth equity firm, today announced the closing of a majority investment in partnership with
management in Gallus BioPharmaceuticals, LLC (“Gallus” or the “Company”), a premier biologics contract
manufacturing organization based in St. Louis, MO. The financial terms of the transaction were not disclosed.

Gallus is a contract manufacturer of clinical and commercial-grade bulk biologics products. The investment from
Ridgemont facilitated Gallus’ acquisition of an existing FDA-approved, commercially-certified biologics
manufacturing plant from Centocor Biologics, LLC. The plant currently manufactures two of Centocor Biologics’ 
leading products, Remicade and Stelara, which are distributed globally. Ridgemont’s investment will also be used to
expand the facility’s manufacturing capabilities, including building a clinical services suite and expanding the existing
development lab.

Gallus is led by President and CEO Mark Bamforth, a former executive with Genzyme Corp., along with an
experienced team of senior executives including Shelly Adams, Vice President of Sales and Marketing, Steven
Kasok, Chief Financial Officer and Mark Bell, Vice President of Site Operations.

“We are delighted to partner with the Ridgemont team,” said Mark Bamforth, President and CEO of Gallus.
“Ridgemont’s experience in healthcare was particularly attractive to us as we sought the best investor to help us
execute our growth strategies and achieve our goal of becoming a leading biologics contract manufacturing partner
providing innovative, flexible manufacturing solutions to biopharmaceutical companies.” 

“We are extremely pleased to form a partnership with Mark Bamforth and his senior leadership team,” said Jack 
Purcell, a Principal at Ridgemont who will join the Gallus Board of Directors. “We see a tremendous market
opportunity in the biologics contract manufacturing space and believe the facility we’ve acquired is well-positioned to
meet the current and future market needs of our customers.” 

“The Ridgemont team has a nearly two decade-long history of successfully investing in healthcare and industrials
transactions, and we expect that experience to be particularly relevant in helping Gallus grow over the life of our
investment in the Company,” said Walker Poole, a Partner at Ridgemont, who will also join the Gallus Board of
Directors. “We plan to build upon our past success with a contract manufacturer of pharmaceutical products, which
was a very successful investment for our firm.” 

Doug Bauche, President of St. Charles region at Enterprise Bank & Trust said “Enterprise is very pleased to partner
with Gallus and Ridgemont in providing the senior financing necessary to complete the acquisition of the Centocor
facility. The investment being made by Gallus and Ridgemont here in St. Louis is significant in many respects. The
retention of jobs and investment in additional plant and equipment makes this a big win for our community.” 

Missouri Governor Jay Nixon visited the Gallus facility on Wednesday, May 18 to participate in an official ribbon-
cutting ceremony.

About Gallus BioPharmaceuticals:

Gallus BioPharmaceuticals is a premier biologics contract manufacturing organization based in St. Louis, MO. Gallus
operates an FDA-approved, commercially-certified facility formerly owned by Centocor Biologics, LLC. The Gallus
facility has capabilities for mammalian cell culture and protein purification in both perfusion and fed batch mode and
will expand to offer additional development and clinical services capabilities. The plant currently produces two
leading commercial biologics products, distributed globally. www.gallusbiopharma.com.
About Ridgemont Equity Partners:

Ridgemont Equity Partners is a Charlotte-based private equity firm that specializes in middle market buyout and
growth equity investments. Since 1993, the principals of Ridgemont have invested over $3 billion in more than 140
companies. The firm focuses on investments of $25 million to $75 million in industries in which it has deep expertise,
including basic industries and services, energy, healthcare, and telecommunications/ media/ technology.
www.ridgemontep.com.

Contacts
BackBay Communications
Jen Dowd, 212-209-3844, x2
Jen.dowd@backbaycommunications.com

				
DOCUMENT INFO
Shared By:
Tags:
Stats:
views:12
posted:5/18/2011
language:English
pages:2
Description: CHARLOTTE, N.C.--(EON: Enhanced Online News)--Ridgemont Equity Partners Acquires Majority Interest in Gallus BioPharmaceuticals a style='font-size: 10px; color: ma
EON: Enhanced Online News EON: Enhanced Online News http://eon.businesswire.com
About At EON: Enhanced Online News, we show you how to make your online press release thrive. If you want to drive traffic to your website, generate sales leads, make an announcement, or promote a new product, EON: Enhanced Online News delivers the online visibility that you need. EON: Enhanced Online News powered by Business Wire.